Market cap
$769 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-75 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
50,231,000
5 Years Aggregate
CFO
$-190.47 Mln
EBITDA
$-183.21 Mln
Net Profit
$-277.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Icosavax Inc (ICVX)
| -2.9 | 0.1 | 47.5 | 82.5 | -- | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Icosavax Inc (ICVX)
| 98.5 | -65.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Icosavax Inc (ICVX)
|
15.3 | 769.0 | 0.0 | -92.6 | -- | -42.8 | -- | 3.3 |
| 23.0 | 492.4 | 37.3 | -30.9 | -102.2 | -1174.5 | -- | 108.4 | |
| 329.8 | 12,599.3 | 0.7 | -433.7 | -75,845.7 | -36.4 | -- | 10.0 |
Shareholding Pattern
View DetailsAbout Icosavax Inc (ICVX)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)... VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC. Read more
-
President, CEO, Co-Founder & Director
Mr. Adam K. Simpson
-
President, CEO, Co-Founder & Director
Mr. Adam K. Simpson
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Icosavax Inc (ICVX)
What is the current share price of Icosavax Inc (ICVX) Today?
The share price of Icosavax Inc (ICVX) is $15.31 (NASDAQ) as of 29-Feb-2024 09:30 EDT. Icosavax Inc (ICVX) has given a return of 82.48% in the last 1 years.
What is the current PB & PE ratio of Icosavax Inc (ICVX)?
Since, TTM earnings of Icosavax Inc (ICVX) is negative, P/E ratio is not available.
The P/B ratio of Icosavax Inc (ICVX) is 3.31 times as on 22-Mar-2024, a 36 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-3.57 |
1.45 |
2021 |
-13.17 |
3.22 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2022 |
-3.57 |
1.45 |
What is the 52 Week High and Low of Icosavax Inc (ICVX)?
The 52-week high and low of Icosavax Inc (ICVX) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Icosavax Inc (ICVX)?
Icosavax Inc (ICVX) has a market capitalisation of $ 769 Mln as on 22-Mar-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Icosavax Inc (ICVX)?
Before investing in Icosavax Inc (ICVX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.